![]() “The new assay from Acutis Diagnostics will be designed to enable clinical researchers to work faster, and with a sound set of insights around their data, ultimately benefitting their current and future patients, as well as the industry as a whole. SOPHiA GENETICS chief revenue officer Ken Freedman said: “Our work at SOPHiA GENETICS is focused on creating technology and solutions that make it easier for everyone to practice and benefit from data-driven medicine. Using SOPHiA GENETICS’ technology, the new assay from Acutis Diagnostics is expected to enhance clinical research and treatments for those with hereditary cancers. The technologies enable clinical researchers to accurately characterise the complex mutational landscape related to major hereditary cancer disorders. SOPHiA GENETICS said that its NGS-based hereditary cancer solutions use artificial intelligence (AI) and machine learning (ML) technologies, with its patented technologies. “Additionally, the test is to provide researchers with a robust set of data and insights to support clinical decision-making and future research.” The new test is said to support genomic screening for patient enrolment in cancer trials and for retrospective analyses to help explain clinical outcomes and drug target discovery.Īcutis Diagnostics chief scientific officer and executive vice president Abdel Halim said: “The use of SOPHiA DDM will help us quickly launch this new assay to aid clinical researchers in speeding up the process for launching select clinical oncology trials and ensuring the most appropriate patients are enrolled. The company will combine SOPHiA DDM for Hereditary Cancers Solution with its laboratory analysis technologies, to create the new assay. The cloud-native platform, dubbed SOPHiA DDM, is designed to analyse data and generate insights from complex multimodal data sets and different diagnostic modalities.Īcutis will develop the new genomic assay, based on its regulatory-approved lab-developed tests (LDTs) that support clinical trials, cancer research and treatment. Acutis is a diagnostic company with a commitment to the best science, technology and practices, all set in motion by a team of deeply committed professionals. (Credit: National Cancer Institute on Unsplash)Īcutis Diagnostics has selected SOPHiA GENETICS, a cloud-native healthcare software company, to use the latter’s platform for developing a new next-generation sequencing (NGS) test. 'Acutis expects that gene sequencing will dramatically improve the way cancer medication is developed and that biomarker-specific treatment will be based on diagnostics, such as those being developed by Acutis,' said Acutis CEO Jibreel Sarij. These services will include research, development, and commercialization of new oncology therapeutics using genomics, including for identifying cancer mutations.’įeatured image: Acutis Diagnostics CEO Jibreel Srij expects gene sequencing to improve how cancer medication is developed and to allow for more targeted treatments.Acutis will develop the new genomic assay, based on its approved lab-developed tests, by combining SOPHiA DDM for Hereditary Cancers Solution with its laboratory analysis technologiesĪcutis selects SOPHiA to create new NGS test. The company plans to provide specialized contract services to assist other biopharmaceutical companies through Acutis Biosciences. “Simply, we demand more of ourselves and each other to serve those who have entrusted us with their important care as best as we can.” “We stress the importance of moving together with continuous improvement in mind,” says Javon Barnwell, vice president of human resources. The company has performed 2.5 million COVID tests over the past two years.Īcutis provides advanced polymerase chain reaction-based (PCR) tests for infectious diseases that may be misdiagnosed with traditional testing, such as urinary tract infections. It was launched as a clinical diagnostic laboratory in a 1,000-square-foot start-up space in Farmingdale.Īcutis also offers molecular testing with a focus on infectious diseases, which enabled it to respond to the COVID-19 pandemic. The company has a 40,000-square-foot facility in Hicksville with more than 200 professional employees. Details Industries Biotechnology Health Care Medical Headquarters Regions Greater New York Area, East Coast, Northeastern US Founded Date 2014 Operating Status Active Legal Name Acutis Diagnostics Inc. “Acutis expects that gene sequencing will dramatically improve the way cancer medication is developed and that biomarker-specific treatment will be based on diagnostics, such as those being developed by Acutis,” says Acutis CEO Jibreel Sarij. It’s new advanced gene sequencing technologies were featured recently in a Long Island Press article. ![]() ![]() The company says it is taking on urgent healthcare issues through the advancement of medical testing capabilities. Acutis Diagnostics, a New York State laboratory, is developing advanced gene sequencing technologies that can be used in the clinic.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |